## SRJR LIFESCIENCES LLP

Building No.3 Plot No .18 Ilabs Center Software units Layout Madhapur - 500081 **LLP IN: AAR-4517** 

Date: 23<sup>rd</sup> December 2020

Listing Department **BSE Limited P J Towers** Mumbai- 400 001

Symbol

: BAFNAPHARMA

Security code : 532989

Dear Sir,

Sub.:- Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to the Resolution Plan approved by the Hon'ble National Company Law Tribunal, Chennai Bench vide its Order dated 1st February, 2019 ("Approved Resolution Plan") the Board of Directors of Bafna Pharmaceuticals Limited had allotted 2,12,90,701 equity shares on 10.09.2020 to SRJR Lifesciences LLP. Please note that SRJR Lifesciences LLP received intimation of shares allotment on 22<sup>nd</sup> October 2020 when such shares were credited to demat account of SRJR Lifesciences LLP. In this regard, please find attached disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

We request you to take it on record.

For SRJR Lifesciences LL

CHINTALAPATI JYOTHI **Designated Partner** 

DIN: 01387376

Tel No: 040-40484444 Email: accounts@ilabsgroup.com

## Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

## Format of Part-A- Details of the Acquisition

Name of the Target Company (TC)	Bafna Phar	maceuticals Limited	
Name(s) of the acquirer and Persons Acting in	SRJR Lifesciences LLP		
Concert (PAC) with the acquirer			
Whether the acquirer belongs to	Promoter		
Promoter/Promoter group			
Name(s) of the Stock Exchange(s) where the shares	National Stock Exchange of India Limited and		
of TC are Listed	BSE Limited		
Details of the acquisition as follows	Number	% w.r.t. total	% w.r.t. total diluted
		share/voting	share/voting capital
		capital	of
		wherever	the TC (**)
		applicable(*)	
Before the acquisition under consideration,			
holding of acquirer along with PACs of:			
a) Shares carrying voting rights	-	-	-
b) Shares in the nature of encumbrance (pledge/	-	-	·
lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by equity	-	-	-
shares			
d) Warrants/convertible securities/any other	-	-	-
instrument that entitles the acquirer to receive			
shares carrying voting rights in the TC (specify			
holding in each category)			
e) Total (a+b+c+d)	-	=	-
Details of acquisition			
a) Shares carrying voting rights acquired	21200701	00.00	
b) VRs acquired otherwise than by equity shares	21290701	90.00	90.00
	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive	-	-	-
shares carrying category) acquired			
d) Shares in the nature of encumbrance (pledge/			
lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+/-d)	21200701	00.00	00.00
c/ Total (arbtct/-u)	21290701	90.00	90.00

	Т			
After the acquisition, holding of acquirer along with PACs of: a) Shares carrying voting rights	21290701	90.00	90.00	
b) VRs otherwise than by equity shares	-	-	-	
c) Warrants/convertible securities/any other	-	(=	-	
instrument that entitles the acquirer to receive				
shares carrying voting rights in the TC (specify				
holding in each category) after acquisition				
d) Shares in the nature of encumbrance (pledge/	-	:-	=	
lien/ non-disposal undertaking/ others)				
e) Total (a+b+c+d)	21290701	90.00	90.00	
Mode of acquisition (e.g. open market / public	Preferential allotment pursuant to the Resolution Plan			
issue / rights issue / preferential allotment / inter-	approved by NCLT, Chennai vide its Order dated 01st			
se transfer/encumbrance, etc.)	February 2019			
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Equity shares			
Date of acquisition of/ date of receipt of intimation	Date of allotment - 10.09.2020, Pursuant to the resolution			
of allotment of shares / VR/ warrants/convertible	plan approved by NCLT, Chennai vide its Order dated 01 <sup>st</sup>			
securities/any other instrument that entitles the	February 2019			
acquirer to receive shares in the TC				
Equity share capital / total voting capital of the TC	2365634			
before the said acquisition				
Equity share capital/ total voting capital of the TC	23656335			
after the said acquisition				
Total diluted share/voting capital of the TC after	23656335			
the said acquisition				